PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies

Rhea-AI Summary

PMGC Capital LLC, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has publicly urged Alaunos Therapeutics (NASDAQ: TCRT) to accept a financing term sheet facilitated through a major Wall Street bank. The term sheet, presented to Alaunos' board on May 25, 2025, is described as a non-toxic, well-structured financing opportunity that could provide substantial capital while potentially creating significant shareholder value. PMGC Capital, which holds a significant ownership position in Alaunos, emphasizes that the opportunity is time-sensitive and represents a strategic path forward. The company commends Alaunos for maintaining a clean capital structure during challenging market conditions and expresses its commitment to working with Alaunos' leadership to enhance long-term shareholder value.

Positive

• Term sheet offers non-toxic, well-structured financing opportunity for Alaunos
• Potential to provide substantial capital while creating shareholder value
• Alaunos maintains a clean capital structure despite challenging market conditions
• Backing from a leading Wall Street bank with successful crypto strategy track record

Negative

• Time-sensitive opportunity may be lost if not acted upon quickly
• Current market conditions described as challenging
• Public pressure on Alaunos board may create tension in negotiations

Insights

Investment Banking Analyst

PMGC Capital, a significant Alaunos shareholder, is publicly pressuring the company to accept a financing term sheet it facilitated through a major bank.

This press release represents a public pressure tactic by PMGC Capital (subsidiary of PMGC Holdings) toward Alaunos Therapeutics. PMGC is leveraging its significant ownership position in Alaunos to publicly urge the company's board to accept a financing term sheet that PMGC facilitated through an unnamed "leading Wall Street Bank."

The financing proposal was apparently sent to Alaunos' board on May 25, 2025, but the company has not yet accepted it. PMGC describes the financing as "non-toxic, well-structured" and claims it would provide "substantial capital" while "potentially creating massive value for shareholders."

This public statement represents an escalation in PMGC's approach. Rather than continuing private negotiations, they're now applying public pressure - a tactic sometimes used when behind-the-scenes discussions aren't progressing. The press release strategically compliments Alaunos for its "clean capital structure" and "prudent financial stewardship" while simultaneously pushing them to accept PMGC's preferred financing arrangement.

The reference to the bank being "behind many Leading Treasury Strategy transactions" appears to be highlighting cryptocurrency expertise, given the explicit mention of "crypto strategies" in the headline. This suggests the proposed financing might involve crypto-related elements, though specific details are not provided.

This situation illustrates the dynamics of activist investing, where a significant shareholder publicly advocates for specific corporate actions. The lack of disclosed terms or specific financing amounts makes it impossible to evaluate the actual merits of the proposal.

NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), today issued a public statement urging Alaunos Therapeutics, Inc. (NASDAQ: TCRT) to accept and act upon the term sheet previously facilitated through a leading Wall Street Bank.

As disclosed in PMGC Capital’s May 14, 2025 press release, available on the PMGC Holdings website, PMGC Capital holds a significant ownership position in Alaunos and continues to act in the best interest of all shareholders.

The proposed financing sent to the board on 5/25/2025, introduced by PMGC Capital and led by a leading wall street bank, represents a compelling, value-aligned opportunity for Alaunos. The bank recently behind many Leading Treasury Strategy transactions that has since garnered widespread institutional attention and market momentum.

“We believe this term sheet offers Alaunos a timely and strategic path forward,” said Braeden Lichti, “This is one of the cleanest financing offers we've seen for a micro-cap company,” said Braeden Lichti, CEO of Northstrive Companies Inc., Manager of PMGC Capital, “It’s non-toxic, well-structured, and provides the company with substantial capital while potentially creating massive value for shareholders. The board should not miss this opportunity.”

PMGC Capital remains committed to working constructively with Alaunos’ Board and management to maximize long-term value and urges them to engage directly with the bank while the opportunity remains actionable.

We commend Alaunos Therapeutics for maintaining a clean capital structure and exercising prudent financial stewardship during challenging market conditions. PMGC Capital looks forward to collaborating with the Alaunos' leadership to pursue initiatives that align with its shared objective of enhancing long-term shareholder value.

About PMGC Capital LLC
A multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. Our mission is to identify and seize high-potential opportunities, delivering sustainable growth and maximizing returns on capital.

About PMGC Holdings Inc.
PMGC Holdings Inc. (“PMGC Holdings”) is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding potential strategic opportunities and the expected benefits thereof. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in the Company’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of PMGC Holdings’ Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

IR Contact:

IR@pmgcholdings.com

FAQ

What is PMGC Capital urging Alaunos Therapeutics (TCRT) to do?

PMGC Capital is urging Alaunos Therapeutics to accept and act upon a financing term sheet facilitated through a leading Wall Street bank that was presented to the board on May 25, 2025.

What type of financing is being offered to Alaunos Therapeutics (TCRT)?

The financing is described as non-toxic and well-structured, designed to provide substantial capital while potentially creating significant shareholder value.

Who is behind the financing offer for Alaunos Therapeutics?

The financing is led by a leading Wall Street bank that has been behind many successful Treasury Strategy transactions, with PMGC Capital facilitating the introduction.

What is PMGC Capital's stake in Alaunos Therapeutics?

PMGC Capital holds a significant ownership position in Alaunos Therapeutics, as disclosed in their May 14, 2025 press release.

How has Alaunos Therapeutics managed its finances according to PMGC?

According to PMGC Capital, Alaunos has maintained a clean capital structure and exercised prudent financial stewardship during challenging market conditions.